Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Sep 5;6(3):1769-92.
doi: 10.3390/cancers6031769.

Drug resistance in cancer: an overview

Genevieve Housman  1 , Shannon Byler  2 , Sarah Heerboth  3 , Karolina Lapinska  4 , Mckenna Longacre  5 , Nicole Snyder  6 , Sibaji Sarkar  7
Affiliations
Review

Drug resistance in cancer: an overview

Genevieve Housman et al. Cancers (Basel). .

Abstract

Cancers have the ability to develop resistance to traditional therapies, and the increasing prevalence of these drug resistant cancers necessitates further research and treatment development. This paper outlines the current knowledge of mechanisms that promote or enable drug resistance, such as drug inactivation, drug target alteration, drug efflux, DNA damage repair, cell death inhibition, and the epithelial-mesenchymal transition, as well as how inherent tumor cell heterogeneity plays a role in drug resistance. It also describes the epigenetic modifications that can induce drug resistance and considers how such epigenetic factors may contribute to the development of cancer progenitor cells, which are not killed by conventional cancer therapies. Lastly, this review concludes with a discussion on the best treatment options for existing drug resistant cancers, ways to prevent the formation of drug resistant cancers and cancer progenitor cells, and future directions of study.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Categories of mechanisms that can enable or promote direct or indirect drug resistance in human cancer cells. These mechanisms can act independently or in combination and through various signal transduction pathways.
Figure 2
Figure 2
Depiction of the primary mechanisms that enable cancer cells to become drug resistant. These include drug inactivation, alteration of drug targets, drug efflux, DNA damage repair, inhibition of cell death, EMT, and epigenetic effects. In the case of EMT, stromal cells assist in this process and signal for improved drug resistance in cancer cells. Cell adhesion molecules on stromal cells and extracellular matrix proteins attach to the cell adhesion molecules on cancer cells. Stromal cells and cancer cells also secrete factors that regulate EMT. The depiction displays a simplified example of these cell interactions.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Zahreddine H., Borden K.L. Mechanisms and insights into drug resistance in cancer. Front. Pharmacol. 2013;4:28. doi: 10.3389/fphar.2013.00028. - DOI - PMC - PubMed
    1. Sampath D., Cortes J., Estrov Z., Du M., Shi Z., Andreeff M., Gandhi V., Plunkett W. Pharmacodynamics of cytarabine alone and in combination with 7-hydroxystaurosporine (UCN-01) in AML blasts in vitro and during a clinical trial. Blood. 2006;107:2517–2574. doi: 10.1182/blood-2005-08-3351. - DOI - PMC - PubMed
    1. Michael M., Doherty M.M. Tumoral drug metabolism: Overview and its implications for cancer therapy. J. Clin. Oncol. 2005;23:205–229. doi: 10.1200/JCO.2005.02.120. - DOI - PubMed
    1. Plastaras J., Guengerich F., Nebert D., Marnett L. Xenobiotic-metabolizing cytochromes P450 convert prostaglandin endoperoxide to hydroxyheptadecatrienoic acid and the mutagen, malondialdehyde. J. Biol. Chem. 2000;275:11784–11790. doi: 10.1074/jbc.275.16.11784. - DOI - PubMed
    1. Shen H., He M., Liu H., Wrighton S., Wang L., Guo B., Li C. Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17. Drug Metab. Dispos. 2007;35:1292–1300. - PubMed